Vanderbilt HIV Clinical Trials Unit (CTU)

项目总结/摘要 艾滋病毒大流行病是对健康和发展的最大持续威胁之一， 识别. NIAID资助的临床试验网络在协调应对 艾滋病毒/艾滋病领域的关键研究问题，这将有助于最终结束艾滋病毒的流行。的 范德比尔特艾滋病毒临床试验单位（CTU）将继续与范德比尔特大学建立伙伴关系， 位于田纳西州纳什维尔的医学中心和位于密苏里州圣路易斯的华盛顿大学， 美国一个艾滋病高发和流行的地区。反恐小组由三个高级 生产性临床研究中心（CRS），有助于三个网络-治疗使命 艾滋病临床试验组（ACTG），艾滋病毒疫苗试验网络（HVTN）的疫苗使命，以及非艾滋病毒临床试验组（ACTG）。 艾滋病毒预防试验网络（HPTN）的疫苗预防使命。范德比尔特疫苗CRS和 自成立以来，华盛顿大学治疗学CRS一直是HVTN和ACTG的成员。 1987年至1988年的网络。范德比尔特治疗CRS于2000年加入ACTG。贡献更多 从那时起，华盛顿大学向HPTN提供了协议特定的注册， 2016年，并建议成为HPTN的正式成员网站，作为华盛顿大学预防和 治疗CRS。该CTU的领导人为该项目做出了具有高度影响力的科学和方案贡献。 包括人类基因组学、当代艾滋病毒相关合并症、神经系统疾病、 艾滋病的各个方面，疫苗反应的免疫学，等等。在建议的资助期内， 范德比尔特CTU将继续为ACTG、HVTN和HPTN的科学研究做出重大贡献。 优先事项范德比尔特和华盛顿大学的ACTG站点将专注于改善健康的策略。 艾滋病毒/艾滋病、结核病和病毒性肝炎患者的生活质量。范德比尔特HVTN网站将提供 研究参与者和尖端的免疫技术，以进一步发展的主要科学优先事项 测试一种安全有效的艾滋病疫苗。华盛顿大学的网站还将有助于 HPTN强调长效剂用于暴露前预防，开发多用途技术 例如将艾滋病毒预防与避孕相结合，以及将生物医学、行为和 结构性预防干预。该CTU的所有CRS都有成功招募的既定记录 临床试验的参与者，并以最大的忠诚度进行研究，以确保参与者的安全和质量 数据推进艾滋病治疗和预防的科学。

PROJECT SUMMARY/ABSTRACT The HIV pandemic is one of the greatest ongoing threats to health and development, over 35 years past its recognition. The NIAID-funded Clinical Trials Networks have played critical roles in the coordinated response to key research questions in the HIV/AIDS field, which will contribute to ultimately ending the HIV epidemic. The Vanderbilt HIV Clinical Trials Unit (CTU) will continue the established partnership between Vanderbilt University Medical Center in Nashville, Tennessee, and Washington University in St. Louis, Missouri, which are located in a region of the United States with high incidence and prevalence of HIV. This CTU comprises three highly productive Clinical Research Sites (CRSs) that contribute to three Networks - the therapeutics mission of the AIDS Clinical Trials Group (ACTG), the vaccine mission of the HIV Vaccine Trials Network (HVTN), and the non- vaccine prevention mission of the HIV Prevention Trials Network (HPTN). The Vanderbilt Vaccine CRS and Washington University Therapeutics CRS have been members of the HVTN and ACTG since the inception of these Networks in 1987-1988. The Vanderbilt Therapeutics CRS joined the ACTG in 2000. To contribute more broadly to the Networks, Washington University has provided protocol-specific enrollment to the HPTN since 2016, and proposes to become a full member site of the HPTN, as the Washington University Prevention & Therapeutics CRS. Leaders of this CTU have made high-impact scientific and programmatic contributions to the Networks in areas that include human genomics, contemporary HIV-associated comorbidities, neurological aspects of HIV disease, immunology of vaccine response, and beyond. During the proposed funding period, the Vanderbilt CTU will continue to make substantial contributions to the ACTG, HVTN and HPTN's scientific priorities. ACTG sites at both Vanderbilt and Washington University will focus on strategies to improve the health of people living with HIV/AIDS, tuberculosis, and viral hepatitis. The Vanderbilt HVTN site will contribute both study participants and cutting-edge immunologic technologies to further the major scientific priority of developing and testing a safe and effective vaccine for HIV. The Washington University site will additionally contribute to HPTN's emphasis on long-acting agents for pre-exposure prophylaxis, developing multipurpose technologies such as combining HIV prevention with contraception, and strategies integrating biomedical, behavioral and structural interventions for prevention. All CRSs of this CTU have an established record of success in enrolling participants to clinical trials and conducting studies with utmost fidelity to ensure participant safety and quality data advancing the science of HIV treatment and prevention.